Exploring Top 5 Companies in the Huntingtons Disease Treatment Market: Emerging Market Trend, Key Market Insights and Future Prospects
RELEASE DATE: Feb 2025 Author: Spherical Insights Request Free Sample
What is Huntingtons Disease Treatment?
Huntingtons disease refers to the genetic condition affecting brain cells to slowly lose function and die. It is a progressive condition possessing symptoms like uncontrollable movements and changes to thinking, behaviour, and personality. Treatment of Huntingtons disease includes medications, therapies, and lifestyle changes. Huntingtons disease treatment drugs including haloperidol, tetrabenazine, and amantadine are especially helpful for controlling unusual movements caused by Huntington's disease. The rise in population prevalence and the increased need for cutting-edge medication types to control the symptoms of the disease are driving the growth of Huntingtons disease treatment market. Furthermore, the market for Huntingtons disease treatment is anticipated to be driven by clinical trials and a robust pipeline of new drugs. An excellent Huntingtons disease treatment market opportunity for investors is the numerous R&D studies for disease-modifying medications.
Key Market Insights
The Global Huntingtons Disease Treatment Market Size is expected to grow from USD 1.23 Billion in 2023 to USD 3.29 Billion by 2033, at a CAGR of 10.34% during the forecast period 2023-2033. There is an increase in the prevalence of Huntingtons disease population and rising demand for advanced drug types for controlling the symptoms associated with Huntingtons disease.
Emerging Market Trend: Disease Modifying Therapies for Huntington’s Disease
Huntington’s disease may be treated with drugs that target huntingtin DNA and RNA, huntingtin protein clearance, DNA repair pathways, and other approaches that focus on inflammation and cell replacement. Disease-modifying therapy is approved for premanifest/prodromal HD. Treatments that target particular facets of HD biology are being created and tested for a potential slowing of disease development, in addition to efforts to treat symptoms. There is a growing attempt at disease-modifying therapies, with a particular focus on interventions aimed at lowering the level of mHTT in the brain.
List of Key Companies
- Teva Pharmaceutical Industries Ltd
- Lundbeck
- F. Hoffmann-La Roche Ltd
- Wave Life Sciences
- uniQure N.V.
- Voyager Therapeutics, Inc.
- SOM Biotech
- Ionis Pharmaceuticals, Inc.
- Sage Therapeutics
- Vertex Pharmaceuticals
- Azevan Pharmaceuticals, Inc.
- Prana Biotechnology
- Mitochon Pharmaceuticals
- Annexon Biosciences
- Pfizer Inc.
- Others
1.Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Is an Israeli multinational pharmaceutical company, specialized primarily in generic drugs, and other business interests such as branded drugs, active pharmaceutical ingredients and, to lesser extent, contract manufacturing services and an out-licensing platform. The company strives to deliver quality medicines to patients around the world with integrity and ethical business practices. Austedo (deutetrabenazine), which is used to treat chorea linked to Huntington's disease and tardive dyskinesia, and Ajovy (fremanezumab), which is intended to prevent adult migraines, are two of Teva's main branded pharmaceuticals. Teva also sells the branded medications Copaxone, Bendeka, and Treanda, all of which are mostly distributed in the US. In January 2025, Teva delivered second consecutive year of growth, announced strong financial results in fourth quarter and full year 2024, led by generics performance and innovative portfolio growth.
2. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. Is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The company produces diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments. Product portfolio includes generics, branded generics, speciality, difficult-to-make technology intensive products, over-the-counter (OTC), anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. Sun Pharmaceutical Industries Ltd. has announced an interim dividend and reported strong Q3FY25 earnings. The company is also working on developing new drugs and expanding its business globally.
3. Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures and markets a wide range of pharmaceuticals in India and overseas, producing over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology. The company focuses on patient needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. Additionally, there is an increasing investments in cutting-edge fields like gene and cell therapies, digital therapeutics, and more. Tetrabenazine Tablets launched by Dr. Reddy’s Laboratories, is a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the United States market approved by the U.S. Food and Drug Administration (USFDA).
4. Lupin Ltd.
Lupin Ltd. is an Indian multinational pharmaceutical company based in Mumbai, is one of the largest generic pharmaceutical companies by revenue globally. Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. Lupin has launched generic tetrabenazine tablets to treat Huntington's disease. Tetrabenazine is a drug that helps control involuntary movements associated with Huntington's disease.
5. Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. The company holds the fifth-leading position in the top 5 Huntington’s disease treatment providers. It is a well-known company that markets a medicine called INGREZZA. The solutions provider focuses on developing cutting-edge medications for conditions related to neurology, neuropsychiatry, and neuroendocrinology.
Future Prospects for Huntingtons Disease Treatment Market
R&D activities for the launch of novel therapeutic alternatives
R&D projects that target the condition’s primary symptoms, such as gene therapy and precision medications, can offer significant prospects for market expansion. Both medicine and support are necessary for symptom management. Novel approaches, such as gene therapies, are being investigated for possible future medical interventions. In order to fix the damaged gene without upsetting the harmony of the entire genetic sequence, scientists are focusing on creating therapies that limit the abnormal production of huntingtin protein. It is still difficult to completely control, though, researchers are concentrating on additional study and treatment.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us